Transplant-related bronchiolitis obliterans

This study tests whether the drug belumosudil can prevent chronic lung allograft dysfunction (CLAD) in people who have had a lung transplant and show signs of rejection or inflammation on a biopsy. About 234 participants will receive either belumosudil or a placebo for 52 weeks, …

This Phase 3 trial tests an oral drug called belumosudil in adults who have chronic lung allograft dysfunction (CLAD) after a bilateral lung transplant. CLAD is a form of chronic rejection that slowly worsens lung function. The study compares belumosudil to a placebo, both given …

This study tests an inhaled drug called LAM-001 in 30 lung transplant patients who have developed chronic rejection (BOS). Participants will inhale LAM-001 or a placebo daily for 48 weeks. The goal is to see if the drug is safe and can slow the decline in lung function.

This study tests whether advanced imaging techniques, including oxygen-enhanced MRI and hyperpolarized xenon MRI, can detect chronic lung allograft dysfunction (CLAD) earlier than standard lung function tests. CLAD is a common complication after lung transplantation that can lead…

This study looks for early signs that a treatment called ECP is working in people who have had a lung transplant and developed chronic rejection (CLAD). Researchers will collect blood samples and, for some, lung MRI scans before, during, and after ECP therapy. The goal is to find…